Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases
DOI: https://doi.org/10.2147/dddt.s451668
IF: 4.3188
2024-03-24
Drug Design Development and Therapy
Abstract:Congcong Wang, 1, &ast Jinyu Xiang, 1, &ast Qingyu Zhang, 1 Jing Li, 1 Yanqing Liu, 2 Jiannan Liu 1 1 Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shangdong, 264000, People's Republic of China; 2 Department Brest Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shangdong, 264000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jiannan Liu, Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, No. 20 Yuhuangding East Road, Yantai, 264000, People's Republic of China, Email Yanqing Liu, Department Brest Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, No. 20 Yuhuangding East Road, Yantai, 264000, People's Republic of China, Email Aim: Approximately 50% of patients diagnosed with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (BC) are estimated to develop brain metastases (BMs). This study was aimed to assess the intracranial efficacy and survival benefits of pyrotinib and capecitabine combination therapy in the treatment of BMs in patients with HER2-positive BC. Methods: A total of 56 HER2-positive BC patients with BMs were treated with 400 mg pyrotinib once daily along with 1000 mg/m 2 capecitabine twice daily for 14 days in 21-day cycles. The patients were allocated into three cohorts: (1) Cohort A composed of patients with newly diagnosed BMs without prior local radiotherapy, (2) Cohort B included patients with stable post-local radiotherapy, and (3) Cohort C composed of patients with progression following local radiotherapy. The primary endpoint was the intracranial objective response rate (CNS-ORR), while secondary endpoints included intracranial disease control rate (CNS-DCR), progression-free survival (PFS), overall survival (OS), safety, as well as QoL. Results: The observed CNS-ORR CNS-ORR of 72.73% (95% CI 51.85– 86.85%) in cohort A, 55% (95% CI 34.21– 74.18%) in cohort B, and 42.86% (95% CI 21.38– 67.41%) in cohort C. The mPFS was 11 months, 8.4 months, and 5.2 months in cohorts A, B, and C, respectively. Diarrhea, accounting for 23.21% of all the patients, was the most common grade 3/4 adverse event related with treatments (6/22 [27.3%] in cohort A, 4/20 [20.0%] in cohort B, and 3/14 [21.4%] in cohort C). However, there were no deaths related with treatments observed. Importantly, the QoL was efficiently maintained throughout the treatment duration. Conclusion: Pyrotinib and capecitabine combination therapy proved significant effectiveness as well as tolerability in treating HER2-positive BC with BMs, yielding satisfactory results, especially in radiotherapy-naive population. Keywords: breast cancer, brain metastases, pyrotinib, capecitabine, HER2, radiotherapy Approximately 20% of breast tumors overexpress human epidermal growth factor receptor 2 (HER2), 1 which is linked to aggressive malignant behavior, poor response to chemotherapy, and higher rates of recurrence and metastasis. 2 Moreover, about 50% of HER2-positive metastatic breast cancer (BC) patients eventually have brain metastases (BMs). 3–5 In recent years, HER2-targeted therapies such as trastuzumab, 6 pertuzumab, 7 lapatinib, 8 trastuzumab emtansine (T-DM1), 9 and other targeted drugs have significantly improved the survival of metastatic HER2-positive BC patients. 10 However, the incidence of BC BMs has been escalating. The treatments of BC with BMs mainly include stereotactic radiosurgery (SRS), surgical resection, as well as whole-brain radiation therapy (WBRT), but the outcomes are suboptimal. 11 Additionally, chemotherapy, endocrine therapy, and anti-HER2 targeted therapy often yield limited results, which could be attributed to the inadequate ability of drugs in penetrating the blood–brain barrier. 12 HER2-targeted agents, such as monoclonal antibodies, tyrosine kinase inhibitors (TKIs), as well as antibody-drug conjugates, have been investigated in BC with BMs. For instance, the CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) study demonstrated that the combination of trastuzumab and pertuzumab significantly delayed BM development compared to trastuzumab alone (15 vs 11.9 months) and prolonged overall survival (OS) (34.4 vs 26.3 months). 13 In the EMILIA study, 14 T-DM1 significantly extended OS among patients with BMs (26.8 months) in contrast with the combination of lapatinib and capecitabine (12.9 months). The KAMILLA study 15 also demonstrat -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal